The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Current pharmaceutical design

• Publication date

  2008-05-31

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.2174/138161208784705487PMID 18673201PMCID PMC2895311
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-beta peptide in a blood-brain barrier in vitro model.

  2008cited by this paper
• Environmental Enrichment Counteracts Alzheimer’s Neurovascular Dysfunction in TgCRND8 Mice

  2008cited by this paper
• The blood-brain barrier in health and chronic neurodegenerative disorders.

  2008cited by this paper
• A shed form of LDL receptor-related protein-1 regulates peripheral nerve injury and neuropathic pain in rodents.

  2008cited by this paper
• Lipocalin-type prostaglandin D synthase/β-trace is a major amyloid β-chaperone in human cerebrospinal fluid

  2007cited by this paper
• Clearance of amyloid-beta by circulating lipoprotein receptors.

  2007cited by this paper
• Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease.

  2007cited by this paper
• Transport Pathways for Clearance of Human Alzheimer's Amyloid β-Peptide and Apolipoproteins E and J in the Mouse Central Nervous System

  2007cited by this paper
• Functional duplication of ligand-binding domains within low-density lipoprotein receptor-related protein for interaction with receptor associated protein, alpha2-macroglobulin, factor IXa and factor VIII.

  2007cited by this paper
• Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide

  2007cited by this paper
• Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans

  2006cited by this paper
• Modulation of β-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family

  2006cited by this paper
• LRP in amyloid-beta production and metabolism.

  2006cited by this paper
• Immunotherapy for conformational diseases.

  2006cited by this paper
• The development of preventives and therapeutics for Alzheimer's disease that inhibit the formation of beta-amyloid fibrils (fAbeta), as well as destabilize preformed fAbeta.

  2006cited by this paper
• Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors.

  2006cited by this paper
• RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease

  2006cited by this paper
• Amyloid double trouble

  2006cited by this paper
• Major Involvement of Low-Density Lipoprotein Receptor-Related Protein 1 in the Clearance of Plasma Free Amyloid β-Peptide by the Liver

  2006cited by this paper
• Genetic–morphologic association study: association between the low density lipoprotein‐receptor related protein (LRP) and cerebral amyloid angiopathy

  2005cited by this paper
• LRP-mediated clearance of Abeta is inhibited by KPI-containing isoforms of APP.

  2005cited by this paper
• IgG-Assisted Age-Dependent Clearance of Alzheimer's Amyloid β Peptide by the Blood–Brain Barrier Neonatal Fc Receptor

  2005cited by this paper
• Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease

  2005cited by this paper
• The Low Density Lipoprotein Receptor-related Protein (LRP) Is a Novel β-Secretase (BACE1) Substrate*

  2005cited by this paper
• Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein.

  2005cited by this paper
• Oxygen Glucose Deprivation Switches the Transport of tPA Across the Blood–Brain Barrier From an LRP-Dependent to an Increased LRP-Independent Process

  2005cited by this paper
• LRP and Alzheimer's Disease

  2005cited by this paper
• P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model.

  2005cited by this paper
• Early-onset and Robust Cerebral Microvascular Accumulation of Amyloid β-Protein in Transgenic Mice Expressing Low Levels of a Vasculotropic Dutch/Iowa Mutant Form of Amyloid β-Protein Precursor*

  2004cited by this paper
• Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier

  2004cited by this paper
• RAGE (Yin) Versus LRP (Yang) Balance Regulates Alzheimer Amyloid &bgr;-Peptide Clearance Through Transport Across the Blood–Brain Barrier

  2004cited by this paper
• Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice.

  2004cited by this paper
• LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms.

  2004cited by this paper
• Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein.

  2004cited by this paper
• ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo.

  2004cited by this paper
• Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis

  2003cited by this paper
• Structural and functional aspects of the blood-brain barrier.

  2003cited by this paper
• Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis.

  2003cited by this paper
• Differential Distribution of Low‐Density Lipoprotein‐Receptor‐Related Protein (LRP) and Megalin in Polarized Epithelial Cells is Determined by Their Cytoplasmic Domains

  2003cited by this paper
• RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain

  2003cited by this paper
• Amyloidosis and Alzheimer's disease.

  2002cited by this paper
• Genetics and molecular biology: phosphorylation of low-density lipoprotein receptor-related protein by platelet-derived growth factor

  2002cited by this paper
• Substitution at codon 22 reduces clearance of Alzheimer's amyloid-beta peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood.

  2002cited by this paper
• Phosphorylation of LRP1: regulation of transport and signal transduction.

  2002cited by this paper
• Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease

  2002cited by this paper
• LRP and senile plaques in Alzheimer's disease: colocalization with apolipoprotein E and with activated astrocytes.

  2002cited by this paper
• Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke.

  2002cited by this paper
• Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions.

  2002cited by this paper
• Differential Functions of Members of the Low Density Lipoprotein Receptor Family Suggested by Their Distinct Endocytosis Rates*

  2001cited by this paper
• Dissection of receptor folding and ligand-binding property with functional minireceptors of LDL receptor-related protein.

  2001cited by this paper
• Metabolic regulation of brain Abeta by neprilysin.

  2001cited by this paper
• Clearing the brain's amyloid cobwebs.

  2001cited by this paper
• LRP: a multifunctional scavenger and signaling receptor.

  2001cited by this paper
• The LDL receptor gene family: (un)expected signal transducers in the brain.

  2001cited by this paper
• The roles of receptor-associated protein (RAP) as a molecular chaperone for members of the LDL receptor family.

  2001cited by this paper
• Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.

  2000cited by this paper
• Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition

  2000cited by this paper
• Clearance of amyloid beta-peptide from brain: transport or metabolism?

  2000cited by this paper
• Candidate genes showing no evidence for association or linkage with Alzheimer's disease using family-based methodologies.

  2000cited by this paper
• Interactions of the Low Density Lipoprotein Receptor Gene Family with Cytosolic Adaptor and Scaffold Proteins Suggest Diverse Biological Functions in Cellular Communication and Signal Transduction*

  2000cited by this paper
• beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1.

  2000cited by this paper
• Association between coding variability in the LRP gene and the risk of late-onset Alzheimer’s disease

  1999cited by this paper
• Alpha2-macroglobulin enhances the clearance of endogenous soluble beta-amyloid peptide via low-density lipoprotein receptor-related protein in cortical neurons.

  1999cited by this paper
• Cerebrovascular Accumulation and Increased Blood‐Brain Barrier Permeability to Circulating Alzheimer's Amyloid β Peptide in Aged Squirrel Monkey with Cerebral Amyloid Angiopathy

  1998cited by this paper
• Low density lipoprotein receptor related protein gene exon 3 polymorphism association with Alzheimer's disease in Chinese.

  1998cited by this paper
• Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer.

  1998cited by this paper
• Interaction of Cytosolic Adaptor Proteins with Neuronal Apolipoprotein E Receptors and the Amyloid Precursor Protein*

  1998cited by this paper
• Nerve Growth Factor Induces Rapid Increases in Functional Cell Surface Low Density Lipoprotein Receptor-related Protein*

  1998cited by this paper
• Association at LRP gene locus with sporadic late-onset Alzheimer's disease.

  1998cited by this paper
• Alzheimer's disease: genotypes, phenotypes, and treatments.

  1997cited by this paper
• Soluble Low Density Lipoprotein Receptor-related Protein (LRP) Circulates in Human Plasma*

  1997cited by this paper
• Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), and apolipoprotein E receptor, with late-onset Alzheimer's disease

  1997cited by this paper
• Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein.

  1997cited by this paper
• Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta.

  1997cited by this paper
• RAP, a specialized chaperone, prevents ligand‐induced ER retention and degradation of LDL receptor‐related endocytic receptors.

  1996cited by this paper
• Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers.

  1996cited by this paper
• RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease.

  1996cited by this paper
• Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid beta in guinea pigs.

  1996cited by this paper
• Multiple, diverse senile plaque–associated proteins are ligands of an apolipoprotein e receptor, the α2‐macroglobulin receptor/low‐density‐lipoprotein receptor—related protein

  1995cited by this paper
• Passage of human amyloid beta-protein 1-40 across the murine blood-brain barrier.

  1994cited by this paper
• Blood-brain barrier transport of circulating Alzheimer's amyloid beta.

  1993cited by this paper
• Transport, uptake, and metabolism of blood-borne vasopressin by the blood-brain barrier.

  1992cited by this paper
• Kinetics and Na independence of amino acid uptake by blood side of perfused sheep choroid plexus.

  1990cited by this paper
• A saturable mechanism for transport of immunoglobulin G across the blood-brain barrier of the guinea pig.

  1990cited by this paper
• Kinetic Analysis of Leucine‐Enkephalin Cellular Uptake at the Luminal Side of the Blood‐Brain Barrier of an In Situ Perfused Guinea‐Pig Brain

  1989cited by this paper
• Transport of Leucine‐Enkephalin Across the Blood‐Brain Barrier in the Perfused Guinea Pig Brain

  1987cited by this paper
• Blood-brain barrier permeability to leucine-enkephalin, D-alanine2-D-leucine5-enkephalin and their N-terminal amino acid (tyrosine).

  1985cited by this paper

• Advanced nanoparticle engineering for precision therapeutics of brain diseases.

  2025cites this paper
• Potential utility of salivary gland amyloid uptake as a surrogate marker for adipose tissue and amyloid-beta dynamics based on its association with BMI and cerebral amyloid burden

  2025cites this paper
• Role and relation of cell death in Alzheimer's disease.

  2025cites this paper
• Histological and Functional Breakdown of the Blood−Brain Barrier in Alzheimer’s Disease: A Multifactorial Intersection

  2025cites this paper
• Mechanisms of action of formononetin, an extract from Astragalus membranaceus medicinal plant, in ameliorating Alzheimer’s disease

  2025cites this paper
• Understanding the Blood-Brain Barrier: From Physiology to Pathology.

  2025cites this paper
• Emerging Biomarkers and Determinants of Lipoprotein Profiles to Predict CVD Risk: Implications for Precision Nutrition

  2024cites this paper
• A review of the roles of pathogens in Alzheimer’s disease

  2024cites this paper
• Precision drug delivery to the central nervous system using engineered nanoparticles

  2024cites this paper
• Understanding the Liver’s Role in the Clearance of Aβ40

  2024cites this paper
• The vascular contribution of apolipoprotein E to Alzheimer's disease.

  2024cites this paper
• Modulation of Oxidative Stress and Neuroinflammation by Cannabidiol (CBD): Promising Targets for the Treatment of Alzheimer’s Disease

  2024cites this paper
• Astrocytic functions and lipid metabolism: Correlations and therapeutic targets in Alzheimer's disease and glioblastoma

  2024cites this paper
• Nonalcoholic Fatty Liver Disease and Longitudinal Change in Imaging and Plasma Biomarkers of Alzheimer Disease and Vascular Pathology

  2024cites this paper
• Underlying Mechanisms and Treatment of Cellular Senescence-Induced Biological Barrier Interruption and Related Diseases

  2023cites this paper
• Exposure to quasi-ultrafine particulate matter accelerates memory impairment and AD neuropathology in the AppNL-G-F knock-in mouse model.

  2023cites this paper
• Plasma Amyloid-β Homeostasis Is Associated with Body Mass Index and Weight Loss in People with Overweight and Obesity

  2023cites this paper
• Endothelial Dysfunction in Neurodegenerative Diseases

  2023cites this paper
• Copper and cuproptosis: new therapeutic approaches for Alzheimer’s disease

  2023cites this paper
• Blood–Brain Barrier Breakdown in Alzheimer’s Disease: Mechanisms and Targeted Strategies

  2023cites this paper
• Integrated in-silico and in-vitro assessments of HDAC6 inhibitor efficacy in mitigating amyloid beta pathology in Alzheimer’s disease

  2023cites this paper
• Lung endothelium, tau, and amyloids in health and disease

  2023cites this paper
• American Ginseng for the Treatment of Alzheimer’s Disease: A Review

  2023cites this paper
• Overlapping Neuroimmune Mechanisms and Therapeutic Targets in Neurodegenerative Disorders

  2023cites this paper
• Models of cerebral amyloid angiopathy-related intracerebral hemorrhage

  2022cites this paper
• N-terminally truncated Aβ4-x proteoforms and their relevance for Alzheimer’s pathophysiology

  2022cites this paper
• Plasma amyloid-beta homeostasis is associated with Body Mass Index and weight-loss in people with overweight and obesity

  2022cites this paper
• Apolipoprotein E in Cardiometabolic and Neurological Health and Diseases

  2022cites this paper
• Soluble LRP-1 in Parkinson’s disease: clues for paradoxical effects

  2022cites this paper
• Contribution of blood-brain barrier-related blood-borne factors for Alzheimer’s disease vs. vascular dementia diagnosis: A pilot study

  2022cites this paper
• Partial Endothelial Nitric Oxide Synthase Deficiency Exacerbates Cognitive Deficit and Amyloid Pathology in the APPswe/PS1ΔE9 Mouse Model of Alzheimer’s Disease

  2022cites this paper
• Naturally Occurring Antioxidant Therapy in Alzheimer’s Disease

  2022cites this paper
• Bioinformatic Annotation of Genes for Alzheimer’s Disease and Coronary Heart Disease

  2021cites this paper
• The Blood–Brain Barrier and CNS Drug Delivery

  2021cites this paper
• Possible effects of Porphyromonas gingivalis on the blood–brain barrier in Alzheimer’s disease

  2021cites this paper
• Bias-generating factors in biofluid amyloid-β measurements for Alzheimer’s disease diagnosis

  2021cites this paper
• Chinese Herbal Medicine Adjusting Brain Microenvironment via Mediating Central Nervous System Lymphatic Drainage in Alzheimer’s Disease

  2021cites this paper
• New advances in brain-targeting nano-drug delivery systems for Alzheimer's disease

  2021influential citation
• Soluble Receptors Affecting Stroke Outcomes: Potential Biomarkers and Therapeutic Tools

  2021cites this paper
• SARS-CoV-2: is there neuroinvasion?

  2021cites this paper
• The Role of Circadian Rhythm in Choroid Plexus Functions.

  2021cites this paper
• In vitro modeling of the neurovascular unit: advances in the field

  2020cites this paper
• Selective transmembrane transport of Aβ protein regulated by tryptophan enantiomers.

  2020cites this paper
• Therapeutic Potential of Direct Clearance of the Amyloid-β in Alzheimer’s Disease

  2020cites this paper
• Ketone Bodies Promote Amyloid-β1–40 Clearance in a Human in Vitro Blood–Brain Barrier Model

  2020cites this paper
• ANG1005, a Brain-Penetrating Peptide–Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases

  2020influential citation
• Age, sex, and regional differences in scavenger receptor CD36 in the mouse brain: Potential relevance to cerebral amyloid angiopathy and Alzheimer's disease

  2020cites this paper
• Progress of RAGE Molecular Imaging in Alzheimer’s Disease

  2020cites this paper
• Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer’s Disease

  2020cites this paper
• The good, the bad, and the opportunities of the complement system in neurodegenerative disease

  2020cites this paper
• The Blood-Brain Barrier Interface in Diabetes Mellitus: Dysfunctions, Mechanisms, and Approaches to Treatment.

  2020cites this paper
• Prosaposin in the rat oviductal epithelial cells

  2020cites this paper
• Pathological Mechanisms Linking Diabetes Mellitus and Alzheimer’s Disease: the Receptor for Advanced Glycation End Products (RAGE)

  2020cites this paper
• Nanotechnology approaches for enhanced CNS delivery in treating Alzheimer's disease

  2019cites this paper
• Cerebrovascular Smooth Muscle Cells as the Drivers of Intramural Periarterial Drainage of the Brain

  2019cites this paper
• The blood–brain barrier as an endocrine tissue

  2019cites this paper
• Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression

  2019cites this paper
• Circulating Neurotoxic 5-HT 2 A Receptor Agonist Autoantibodies in Adult Type 2 Diabetes with Parkinson ’ s Disease Page 3 of 11 Liposorber-LA-15 dextran sulfate cellulose chromatography

  2018cites this paper
• Review of the advances in treatment for Alzheimer disease: Strategies for combating β-amyloid protein.

  2018cites this paper
• Circulating Neurotoxic 5-HT2A Receptor Agonist Autoantibodies in Adult Type 2 Diabetes with Parkinson's Disease.

  2018cites this paper
• Somatostatin Maintains Permeability and Integrity of Blood-Brain Barrier in β-Amyloid Induced Toxicity

  2018cites this paper
• Peptides, Peptidomimetics, and Carbohydrate-Peptide Conjugates as Amyloidogenic Aggregation Inhibitors for Alzheimer's Disease.

  2018cites this paper
• The Coming of Age of the Angiotensin Hypothesis in Alzheimer’s Disease: Progress Toward Disease Prevention and Treatment?

  2018cites this paper
• Elevation of Plasma Amyloid-β Level is More Significant in Early Stage of Cognitive Impairment: A Population-Based Cross-Sectional Study

  2018cites this paper
• The Relation Between Brain Amyloid Deposition, Cortical Atrophy, and Plasma Biomarkers in Amnesic Mild Cognitive Impairment and Alzheimer’s Disease

  2018cites this paper
• Rollercoaster ride of kynurenines: steering the wheel towards neuroprotection in Alzheimer’s disease

  2018cites this paper
• Aβ truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition.

  2018cites this paper
• Neurovascular Alterations in Alzheimer’s Disease: Transporter Expression Profiles and CNS Drug Access

  2017cites this paper
• Targeted delivery of rosmarinic acid across the blood-brain barrier for neuronal rescue using polyacrylamide-chitosan-poly(lactide-co-glycolide) nanoparticles with surface cross-reacting material 197 and apolipoprotein E.

  2017cites this paper
• Insulin differentially affects the distribution kinetics of amyloid beta 40 and 42 in plasma and brain

  2017cites this paper
• Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities

  2017influential citation
• The underexplored question of β-amyloid monomers.

  2017cites this paper
• Soluble lipoprotein receptor-related protein immunoreactive species in cell culture media and serum replacement supplements

  2017cites this paper
• The Blood-Brain Barriers

  2017cites this paper
• Neuroprotection against apoptosis of SK-N-MC cells using RMP-7- and lactoferrin-grafted liposomes carrying quercetin

  2017cites this paper
• Understanding the functions and relationships of the glymphatic system and meningeal lymphatics.

  2017cites this paper
• Identification and functional characterization of a novel member of low-density lipoprotein receptor-related protein (LRP)-like family in amphioxus.

  2017cites this paper
• Review of the advances in treatment for Alzheimer disease: Strategies for combating β-amyloid protein.

  2017cites this paper
• Suppression of Alzheimer's disease-related phenotypes by the heat shock protein 70 inducer, geranylgeranylacetone, in APP/PS1 transgenic mice via the ERK/p38 MAPK signaling pathway

  2017cites this paper
• Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment

  2016cites this paper
• Alzheimer’s Disease Risk Genes and Lipid Regulators

  2016cites this paper
• Phytosterols and Dementia

  2016cites this paper
• In vivo Differential Brain Clearance and Catabolism of Monomeric and Oligomeric Alzheimer's Aβ protein

  2016cites this paper
• Amyloid-β and Astrocytes Interplay in Amyloid-β Related Disorders

  2016cites this paper
• Chronic cerebral hypoperfusion-induced impairment of Aβ clearance requires HB-EGF-dependent sequential activation of HIF1α and MMP9.

  2016cites this paper
• Current Research Therapeutic Strategies for Alzheimer's Disease Treatment

  2016cites this paper
• The multiple faces of RAGE – opportunities for therapeutic intervention in aging and chronic disease

  2016cites this paper
• Alzheimer Disease and Its Growing Epidemic: Risk Factors, Biomarkers, and the Urgent Need for Therapeutics.

  2016cites this paper
• The role of insulin in the vascular contributions to age-related dementia.

  2016cites this paper
• Copper Exposure Perturbs Brain Inflammatory Responses and Impairs Clearance of Amyloid-Beta.

  2016cites this paper
• Role of Hydrophobic Patch in LRP6: A Promising Drug Target for Alzheimer's disease

  2016cites this paper
• Origin(s) of Intraneuronal Amyloid

  2016cites this paper
• Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer’s Disease: A Systematic Review and Meta-Analysis

  2016cites this paper
• The role of high-fat diet in an APP/PS1 model of familial Alzheimer disease = Efecto de una dieta rica en grasas en ratones APP/PS1, modelo familiar de la enfermedad de Alzheimer

  2015cites this paper
• Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer’s disease

  2015cites this paper
• Alzheimer's disease, astrocytes and kynurenines.

  2015cites this paper
• Modeling the Role of the Glymphatic Pathway and Cerebral Blood Vessel Properties in Alzheimer’s Disease Pathogenesis

  2015cites this paper
• Evidence against a role of P-glycoprotein in the clearance of the Alzheimer’s disease Aβ1–42 peptides

  2015cites this paper
• Vascular Factors and the Blood Brain Barrier in Alzheimer’s Disease, Parkinson’s Disease and Amyotrophic Lateral Sclerosis

  2015cites this paper
• Targeting delivery of liposomes with conjugated p-aminophenyl-α-d-manno-pyranoside and apolipoprotein E for inhibiting neuronal degeneration insulted with β-amyloid peptide

  2015cites this paper